Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

Delayed Quote. Delayed  - 07/25 05:35:29 pm
4653.5 GBp   +0.89%
07/25DJASTRAZENECA : 2Q 2016 -- Forecast
07/19DJValeant Gets FDA Panel Recommendation for Psoriasis Drug
07/19DJASTRAZENECA : Gets EU Approval for Qtern to Treat Type 2 Diabetes
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

AstraZeneca plc : AstraZeneca and Bristol-Myers Squibb resubmit dapagliflozin New Drug Application for the treatment of type 2 diabetes in the U.S

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/25/2013 | 02:26pm CEST

AstraZeneca and Bristol-Myers Squibb today announced they have resubmitted to the U.S. Food and Drug Administration (FDA), a New Drug Application (NDA) for dapagliflozin for the treatment of adults with type 2 diabetes.

The NDA resubmission, which is pending acceptance by the FDA, includes several new studies and additional long-term data (up to four years' duration) from previously submitted studies.

NOTES TO EDITORS About dapagliflozin

Dapagliflozin, an investigational compound, is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2), which works independently of insulin. It is currently approved for the treatment of type 2 diabetes in the European Union, Australia, Brazil, Mexico and New Zealand.

About Type 2 Diabetes

In 2012, diabetes was estimated to affect more than 370 million people worldwide. The prevalence of diabetes is projected to reach more than 550 million by 2030. Type 2 diabetes accounts for approximately 90 to 95% of all cases of diagnosed diabetes in adults. Type 2 diabetes is a chronic disease characterised by insulin resistance and dysfunction of beta cells in the pancreas, leading to elevated glucose levels. Over time, this sustained hyperglycemia contributes to further progression of the disease. Significant unmet needs still exist, as many patients remain inadequately controlled on their current glucose-lowering regimen.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.www.astrazeneca.com

CONTACTS Media Enquiries

Esra Erkal-Paler +44 20 7604 8030 (UK/Global)
Vanessa Rhodes +44 20 7604 8037 (UK/Global)
Ayesha Bharmal +44 20 7604 8034 (UK/Global)
Michele Meixell +1 302 885 2677 (US)
Jacob Lund +46 8 553 260 20 (Sweden)

Colleen Proctor + 44 207 604 8128 mob: +1 302 357 4882
Ed Seage + 44 207 604 8125 mob: +1 302 373 1361

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA PLC
07/25DJASTRAZENECA : 2Q 2016 -- Forecast
07/20 ASTRAZENECA : Senators Collins, McCaskill Seek More Information on AstraZeneca's..
07/20 ASTRAZENECA : McCaskill Requests Information from AstraZeneca on Popular Drug Cr..
07/19DJValeant Gets FDA Panel Recommendation for Psoriasis Drug
07/19DJASTRAZENECA : Gets EU Approval for Qtern to Treat Type 2 Diabetes
07/19 ASTRAZENECA : QTERN (saxa/dapa) EU approved for type-2 diabetes
07/19 ASTRAZENECA : Qtern Gets European Approval For Type 2 Diabetes
07/18 ASTRAZENECA : TAGRISSO® (OSIMERTINIB) Met Primary Endpoint in Phase III 2nd-Line..
07/18 LONDON MARKET OPEN : ARM Leads Rising Market But Tour Operators Down
07/18DJASTRAZENECA : Tagrisso Met Primary Endpoint in Lung Cancer Trial
More news
Sector news : Pharmaceuticals - NEC
07/25DJGilead Sales of Hepatitis C Drugs Fall 19%
07/25DJSTADA ARZNEIMITTEL : Feels More Heat From Active Ownership
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJBAYER : 2Q 2016 -- Forecast
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/25 RETIREMENT STRATEGY : 5 Pharmaceutical Dividends To Buy Here
07/22 For The Real Relypsa Puzzle Look Beyond The Takeover
07/22 BIOTECH FORUM DAILY DIGEST : Relypsa Gets Bought Out, Biogen's Big Beat, Biotech..
07/21 Big Pharma Dominates Healthcare But Caregivers Are Top Sector Yield Dogs In J..
07/21 FDA Experts Back Brodalumab, With Warnings
Advertisement
Financials ($)
Sales 2016 23 079 M
EBIT 2016 5 372 M
Net income 2016 2 528 M
Debt 2016 10 708 M
Yield 2016 4,61%
P/E ratio 2016 29,09
P/E ratio 2017 27,55
EV / Sales 2016 3,78x
EV / Sales 2017 3,84x
Capitalization 76 448 M
More Financials
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 68,0 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Edward Bradley Senior VP-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC-0.09%77 183
JOHNSON & JOHNSON21.72%343 913
PFIZER INC.13.82%222 823
NOVARTIS AG-5.13%219 526
ROCHE HOLDING LTD.-9.62%218 832
MERCK & CO., INC.11.36%162 815
More Results